Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans

Detalhes bibliográficos
Autor(a) principal: Meyer, Christian
Data de Publicação: 2006
Outros Autores: Pimenta, Walkyria, Woerle, Hans J., Van Haeften, Timon, Szoke, Ervin, Mitrakou, Asimina, Gerich, John
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.2337/dc06-0438
http://hdl.handle.net/11449/219396
Resumo: OBJECTIVE - To compare the pathophysiology of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) in a more comprehensive and standardized fashion than has hitherto been done. RESEARCH DESIGN AND METHODS - We studied 21 individuals with isolated IFG (IFG/normal glucose tolerance [NGT]), 61 individuals with isolated IGT (normal fasting glucose [NFG]/IGT), and 240 healthy control subjects (NFG/NGT) by hyperglycemic clamps to determine first- and second-phase insulin release and insulin sensitivity. Homeostasis model assessment (HOMA) indexes of β-cell function (HOMA-%B) and insulin resistance (HOMA-IR) were calculated from fasting plasma insulin and glucose concentrations. RESULTS - Compared with NFG/NGT, IFG/NGT had similar fasting insulin concentrations despite hyperglycemia; therefore, HOMA-IR was increased ∼30% (P < 0.05), but clampdetermined insulin sensitivity was normal (P > 0.8). HOMA-%B and first-phase insulin responses were reduced ∼35% (P < 0.002) and ∼30% (P < 0.02), respectively, but second-phase insulin responses were normal (P > 0.5). NFG/IGT had normal HOMA-IR but ∼15% decreased clamp-determined insulin sensitivity (P < 0.03). Furthermore, HOMA-%B was normal but both first-phase (P < 0.0003) and second-phase (P < 0.0001) insulin responses were reduced ∼30%. IFG/NGT differed from NFG/IGT by having ∼40% lower HOMA-%B (P < 0.012) and ∼50% greater second-phase insulin responses (P < 0.005). CONCLUSIONS - Since first-phase insulin responses were similarly reduced in IFG/NGT and NFG/IGT, we conclude that IFG is due to impaired basal insulin secretion and preferential resistance of glucose production to suppression by insulin, as reflected by fasting hyperglycemia despite normal plasma insulin concentrations and increased HOMA-IR, whereas IGT mainly results from reduced second-phase insulin release and peripheral insulin resistance, as reflected by reduced clamp-determined insulin sensitivity. © 2006 by the American Diabetes Association.
id UNSP_a6183ac2bf63d4f0f565fcd1bcd85aae
oai_identifier_str oai:repositorio.unesp.br:11449/219396
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humansOBJECTIVE - To compare the pathophysiology of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) in a more comprehensive and standardized fashion than has hitherto been done. RESEARCH DESIGN AND METHODS - We studied 21 individuals with isolated IFG (IFG/normal glucose tolerance [NGT]), 61 individuals with isolated IGT (normal fasting glucose [NFG]/IGT), and 240 healthy control subjects (NFG/NGT) by hyperglycemic clamps to determine first- and second-phase insulin release and insulin sensitivity. Homeostasis model assessment (HOMA) indexes of β-cell function (HOMA-%B) and insulin resistance (HOMA-IR) were calculated from fasting plasma insulin and glucose concentrations. RESULTS - Compared with NFG/NGT, IFG/NGT had similar fasting insulin concentrations despite hyperglycemia; therefore, HOMA-IR was increased ∼30% (P < 0.05), but clampdetermined insulin sensitivity was normal (P > 0.8). HOMA-%B and first-phase insulin responses were reduced ∼35% (P < 0.002) and ∼30% (P < 0.02), respectively, but second-phase insulin responses were normal (P > 0.5). NFG/IGT had normal HOMA-IR but ∼15% decreased clamp-determined insulin sensitivity (P < 0.03). Furthermore, HOMA-%B was normal but both first-phase (P < 0.0003) and second-phase (P < 0.0001) insulin responses were reduced ∼30%. IFG/NGT differed from NFG/IGT by having ∼40% lower HOMA-%B (P < 0.012) and ∼50% greater second-phase insulin responses (P < 0.005). CONCLUSIONS - Since first-phase insulin responses were similarly reduced in IFG/NGT and NFG/IGT, we conclude that IFG is due to impaired basal insulin secretion and preferential resistance of glucose production to suppression by insulin, as reflected by fasting hyperglycemia despite normal plasma insulin concentrations and increased HOMA-IR, whereas IGT mainly results from reduced second-phase insulin release and peripheral insulin resistance, as reflected by reduced clamp-determined insulin sensitivity. © 2006 by the American Diabetes Association.Department of Endocrinology Carl T. Hayden VA Medical Center, Phoenix, AZDepartment of Clinical Medicine Faculdade de Medicina Botucatu University of Sao Paulo State, Sao PauloDepartment of Internal Medicine II Ludwig-Maximilians University of Munich, MunichDepartment of Internal Medicine University Medical Center Utrecht, UtrechtDepartment of Medicine University of Rochester School of Medicine, Rochester, NYDiabetes/Metabolism Unit Henry Dunant Foundation, AthensCarl T. Hayden VA Medical Center, 650 East Indian School Rd., Phoenix, AZ 85012Carl T. Hayden VA Medical CenterUniversidade de São Paulo (USP)Ludwig-Maximilians University of MunichUniversity Medical Center UtrechtUniversity of Rochester School of MedicineHenry Dunant FoundationMeyer, ChristianPimenta, WalkyriaWoerle, Hans J.Van Haeften, TimonSzoke, ErvinMitrakou, AsiminaGerich, John2022-04-28T18:55:17Z2022-04-28T18:55:17Z2006-08-07info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1909-1914http://dx.doi.org/10.2337/dc06-0438Diabetes Care, v. 29, n. 8, p. 1909-1914, 2006.0149-5992http://hdl.handle.net/11449/21939610.2337/dc06-04382-s2.0-33746617223Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengDiabetes Careinfo:eu-repo/semantics/openAccess2022-04-28T18:55:17Zoai:repositorio.unesp.br:11449/219396Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T16:47:38.105780Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans
title Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans
spellingShingle Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans
Meyer, Christian
title_short Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans
title_full Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans
title_fullStr Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans
title_full_unstemmed Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans
title_sort Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans
author Meyer, Christian
author_facet Meyer, Christian
Pimenta, Walkyria
Woerle, Hans J.
Van Haeften, Timon
Szoke, Ervin
Mitrakou, Asimina
Gerich, John
author_role author
author2 Pimenta, Walkyria
Woerle, Hans J.
Van Haeften, Timon
Szoke, Ervin
Mitrakou, Asimina
Gerich, John
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Carl T. Hayden VA Medical Center
Universidade de São Paulo (USP)
Ludwig-Maximilians University of Munich
University Medical Center Utrecht
University of Rochester School of Medicine
Henry Dunant Foundation
dc.contributor.author.fl_str_mv Meyer, Christian
Pimenta, Walkyria
Woerle, Hans J.
Van Haeften, Timon
Szoke, Ervin
Mitrakou, Asimina
Gerich, John
description OBJECTIVE - To compare the pathophysiology of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) in a more comprehensive and standardized fashion than has hitherto been done. RESEARCH DESIGN AND METHODS - We studied 21 individuals with isolated IFG (IFG/normal glucose tolerance [NGT]), 61 individuals with isolated IGT (normal fasting glucose [NFG]/IGT), and 240 healthy control subjects (NFG/NGT) by hyperglycemic clamps to determine first- and second-phase insulin release and insulin sensitivity. Homeostasis model assessment (HOMA) indexes of β-cell function (HOMA-%B) and insulin resistance (HOMA-IR) were calculated from fasting plasma insulin and glucose concentrations. RESULTS - Compared with NFG/NGT, IFG/NGT had similar fasting insulin concentrations despite hyperglycemia; therefore, HOMA-IR was increased ∼30% (P < 0.05), but clampdetermined insulin sensitivity was normal (P > 0.8). HOMA-%B and first-phase insulin responses were reduced ∼35% (P < 0.002) and ∼30% (P < 0.02), respectively, but second-phase insulin responses were normal (P > 0.5). NFG/IGT had normal HOMA-IR but ∼15% decreased clamp-determined insulin sensitivity (P < 0.03). Furthermore, HOMA-%B was normal but both first-phase (P < 0.0003) and second-phase (P < 0.0001) insulin responses were reduced ∼30%. IFG/NGT differed from NFG/IGT by having ∼40% lower HOMA-%B (P < 0.012) and ∼50% greater second-phase insulin responses (P < 0.005). CONCLUSIONS - Since first-phase insulin responses were similarly reduced in IFG/NGT and NFG/IGT, we conclude that IFG is due to impaired basal insulin secretion and preferential resistance of glucose production to suppression by insulin, as reflected by fasting hyperglycemia despite normal plasma insulin concentrations and increased HOMA-IR, whereas IGT mainly results from reduced second-phase insulin release and peripheral insulin resistance, as reflected by reduced clamp-determined insulin sensitivity. © 2006 by the American Diabetes Association.
publishDate 2006
dc.date.none.fl_str_mv 2006-08-07
2022-04-28T18:55:17Z
2022-04-28T18:55:17Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.2337/dc06-0438
Diabetes Care, v. 29, n. 8, p. 1909-1914, 2006.
0149-5992
http://hdl.handle.net/11449/219396
10.2337/dc06-0438
2-s2.0-33746617223
url http://dx.doi.org/10.2337/dc06-0438
http://hdl.handle.net/11449/219396
identifier_str_mv Diabetes Care, v. 29, n. 8, p. 1909-1914, 2006.
0149-5992
10.2337/dc06-0438
2-s2.0-33746617223
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Diabetes Care
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 1909-1914
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808128701979688960